The rationale for using hydroxycarbamide in the treatment of sickle cell disease” (Haematologica 2011;96:488–491). Reply

Схожие документы

• Reply to Comment on “Stability of human rapamycin-expanded CD4(+)CD25(+) T-regulatory cells” Haematologica 2011;96(9):1357–65
  по: Tresoldi, Eleonora, et al.
  Опубликовано: (2012)
• MonoMAC versus idiopathic CD4(+) lymphocytopenia. Comment to Haematologica. 2011;96(8):1221–5
  по: Chu, Vicki H., et al.
  Опубликовано: (2012)
• Comment on “Stability of human rapamycin-expanded CD4(+)CD25(+) T regulatory cells” Haematologica 2011;96(9):1357–65
  по: He, Haiqi, et al.
  Опубликовано: (2012)
• Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed” Haematologica 2011;96(12):1779–82
  по: Lauseker, Michael, et al.
  Опубликовано: (2012)
• The rationale for using hydroxycarbamide in the treatment of sickle cell disease
  по: Rees, David C.
  Опубликовано: (2011)